Received Sep 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | IM |
injection site pain; muscle pain; headache; nausea and vomiting; nausea and vomiting; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (injection site pain), MYALGIA (muscle pain), HEADACHE (headache), VOMITING (nausea and vomiting) and NAUSEA (nausea and vomiting) in a 64-year-old male patient who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. No Medical History information was reported. On 14-Sep-2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form. On 14-Sep-2025, the patient experienced VACCINATION SITE PAIN (injection site pain), MYALGIA (muscle pain), HEADACHE (headache), VOMITING (nausea and vomiting) and NAUSEA (nausea and vomiting). At the time of the report, VACCINATION SITE PAIN (injection site pain), MYALGIA (muscle pain), HEADACHE (headache) and VOMITING (nausea and vomiting) had not resolved and NAUSEA (nausea and vomiting) outcome was unknown. The concomitant medication was not reported by the reporter. The patient had injection site pain, muscle pain, headache, nausea and vomiting. It was unknown if the patient experienced any additional symptoms or events. The treatment medication was not reported by the reporter.